Buy Medroxyprogesterone

Medroxyprogesterone

Medroxyprogesterone: Generic Medication Overview

Medroxyprogesterone is a synthetic progestogen used in women’s health. In Hong Kong it is classified as a prescription-only medication and is supplied in pill form in strengths of 5 mg and 10 mg. The active ingredient is medroxyprogesterone acetate, a hormone that mimics the effects of natural progesterone. It is marketed under several brand names worldwide, but the content of this article focuses on the generic medication itself.

How Medroxyprogesterone Works in the Body

• Receptor binding - Medroxyprogesterone binds to progesterone receptors in the uterus, breast, and central nervous system. This activation reproduces the physiological actions of endogenous progesterone.
• Endometrial effects - By stabilising the uterine lining, the drug prevents excessive growth of endometrial tissue and reduces irregular bleeding.
• Hormonal feedback - It suppresses the mid-cycle surge of luteinising hormone (LH), thereby inhibiting ovulation when used in higher-dose regimens.
• Onset and duration - Oral administration leads to measurable plasma concentrations within 2-4 hours; the pharmacologic effect typically lasts through the dosing period and diminishes after the drug is stopped.
• Metabolism - The tablet is absorbed from the gastrointestinal tract, undergoes hepatic metabolism primarily via CYP3A4, and is excreted in the urine as inactive metabolites.

Conditions Treated by Medroxyprogesterone

• Secondary amenorrhea - Absence of menstrual periods for at least three months not due to pregnancy.
• Dysfunctional uterine bleeding (DUB) - Abnormal uterine bleeding not related to structural disease.
• Endometriosis-related pain - Medroxyprogesterone helps atrophy ectopic endometrial tissue.
• Prevention of estrogen-induced endometrial hyperplasia - Used in combination with estrogen therapy for women who have not undergone a hysterectomy.

These uses are approved by the Hong Kong Department of Health for prescription-only administration to adult women.

Patient Suitability and Contraindications

Who Should Use Medroxyprogesterone?

• Women of reproductive age who require hormonal regulation of the menstrual cycle.
• Patients receiving estrogen therapy who have an intact uterus and need protection against endometrial overgrowth.

Absolute Contraindications

• Known or suspected pregnancy.
• Current or past history of breast cancer.
• Active thromboembolic disease (deep-vein thrombosis, pulmonary embolism).
• Unexplained vaginal bleeding of unknown origin.
• Severe hepatic impairment (Child-Pugh class C).

Relative Contraindications

• Uncontrolled hypertension.
• Severe migraine with aura.
• History of gallbladder disease.
• Age > 65 years (use with caution).
• Renal impairment (CrCl < 30 mL/min) - dose adjustment may be required.

Special Populations

• Pregnancy & lactation - Contraindicated in pregnancy; breastfeeding women should avoid use unless benefits outweigh risks.
• Elderly - Monitor for cardiovascular and thrombotic events; consider lower starting dose.

Safety Profile: Side Effects and Interactions

Common Side Effects

• Headache - Usually mild and transient.
• Nausea or abdominal discomfort - May lessen after the first few doses.
• Breast tenderness - Often resolves without intervention.
• Weight gain or fluid retention - Reported in up to 5 % of users.
• Mood changes - Including irritability or mild depression.

Serious Adverse Events

• Thromboembolic events - Deep-vein thrombosis, pulmonary embolism; seek urgent medical care if swelling, pain, or shortness of breath occur.
• Severe hepatic dysfunction - Jaundice, dark urine, or unexplained fatigue.
• Adrenal crisis - Rare but possible in patients with adrenal insufficiency; symptoms include hypotension, hyponatremia, and hypoglycemia.

Drug Interactions

• CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) - May increase medroxyprogesterone plasma levels; dose reduction may be needed.
• CYP3A4 inducers (e.g., rifampin, carbamazepine) - May lower effectiveness; consider alternative therapy.
• Anticoagulants - Additive risk of bleeding when combined with warfarin or direct oral anticoagulants; monitor INR or relevant coagulation parameters.
• Hormonal contraceptives - Concomitant use can increase overall progestogenic exposure; assess need for dose adjustment.

Food and Lifestyle Interactions

• The tablet can be taken with or without food; a light meal may reduce occasional stomach upset.
• Grapefruit juice may inhibit CYP3A4 and modestly raise drug levels - avoid excessive consumption.
• Alcohol in moderation does not generally alter efficacy, but heavy drinking can exacerbate liver strain.
• Dizziness is uncommon but possible; avoid operating heavy machinery if you feel unsteady.

How to Take Medroxyprogesterone

• Standard dosing - For short-course treatment of amenorrhea or DUB, the typical regimen is 10 mg orally once daily for 10 days each menstrual cycle. For maintenance therapy, a physician may prescribe 5 mg once daily or an alternate schedule based on clinical response.
• Renal or hepatic impairment - Start with the lower 5 mg dose and titrate cautiously; monitor liver function tests.
• Administration - Swallow the tablet whole with a full glass of water. Do not crush or chew unless instructed by a pharmacist.
• Missed dose - If you remember within 12 hours, take the missed tablet; otherwise skip it and continue the regular schedule. Do not double the next dose.
• Overdose - Symptoms may include nausea, vomiting, severe abdominal pain, or unexpected vaginal bleeding. Seek emergency medical attention; activated charcoal may be considered if presentation is early.
• Discontinuation - For short courses, abrupt cessation is acceptable. For long-term therapy, a gradual taper (e.g., reducing from 10 mg to 5 mg over several weeks) may reduce withdrawal bleeding.

Monitoring and Follow-Up

• Baseline labs - Liver function tests (ALT, AST, bilirubin) and a complete blood count before initiating therapy.
• Blood pressure - Check at the start and periodically, especially in patients with hypertension.
• Endometrial assessment - In women using medroxyprogesterone for long-term estrogen protection, periodic pelvic ultrasound may be advised to rule out hyperplasia.
• Symptoms review - Patients should report any leg swelling, shortness of breath, severe abdominal pain, or unusual bruising promptly.

Storage and Handling

• Keep tablets in the original container, tightly closed, at room temperature (15-30 °C), away from excess moisture and heat.
• Do not store in the bathroom or near kitchen appliances.
• Keep out of reach of children and pets.
• Dispose of unused medication according to local pharmacy take-back programs or the “do not flush” guidelines on the packaging.

Medication-Specific Glossary

Progestogen

A synthetic compound that mimics the activity of natural progesterone, influencing the menstrual cycle and uterine lining.

Dysfunctional Uterine Bleeding (DUB)

Abnormal bleeding from the uterus not caused by structural lesions, infection, or pregnancy.

Endometrial Hyperplasia

Thickening of the uterine lining that can precede abnormal bleeding or, rarely, cancer; often prevented by progestogen therapy when estrogen is given.

Thromboembolism

Formation of a blood clot that travels through the bloodstream, potentially blocking vessels in the lung, brain, or legs.

Medical Disclaimer

This article provides educational information about medroxyprogesterone and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.